Who are Predema's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Neurontin, Oxtriphylline, Theophyllin, Lexiscan, gabapentine, Aminophyllin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/pamabrom.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Predema — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Predema (pamabrom) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: pamabrom. Area: Nephrology.

marketed pamabrom Adenosine receptor A1 Nephrology Live · refreshed every 30 min

Target snapshot

Predema (pamabrom).

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Predema TARGET	pamabrom		marketed	pamabrom	Adenosine receptor A1
Neurontin	gabapentin	Generic (originally Parke-Davis/Pfizer)	marketed	Gabapentinoid (anticonvulsant/neuropathic pain agent)	Large neutral amino acids transporter small subunit 1, Adenosine receptor A1, Alpha-2A adrenergic receptor	1993-12-30
Oxtriphylline	choline theophyllinate	Warner Chilcott Llc	marketed	choline theophyllinate	Adenosine receptor A3, Alkaline phosphatase, tissue-nonspecific isozyme, Adenosine receptor A1	1981-01-01
Theophyllin	Theophyllin	University of Bergen	marketed		Adenosine receptor A3, Alkaline phosphatase, tissue-nonspecific isozyme, Adenosine receptor A1
Lexiscan	Lexiscan	Medical University of South Carolina	marketed		Adenosine receptor A3, Adenosine receptor A1, Adenosine receptor A2a
gabapentine	gabapentine	Dominik Irnich	marketed		Large neutral amino acids transporter small subunit 1, Adenosine receptor A1, Alpha-2A adrenergic receptor
Aminophyllin	Aminophyllin	University of Padova	marketed		Adenosine receptor A3, Alkaline phosphatase, tissue-nonspecific isozyme, Adenosine receptor A1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (pamabrom class)

· 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Predema — Competitive Intelligence Brief. https://druglandscape.com/ci/pamabrom. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing